このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA RCT) (HEAL-FHA)

2026年11月6日 更新者:Hedvig Engberg、Karolinska Institutet

A Digital Psychoeducational Self-help Program Versus Usual Care to Restore Ovulatory Menstrual Cycles in Women With Functional Hypothalamic Amenorrhea: a Randomized Controlled Trial (HEAL-FHA RCT)

The goal of this clinical trial is to learn whether a 10-week digital psychoeducational health and lifestyle program can help women with functional hypothalamic amenorrhea (FHA) recover ovulatory menstrual cycles and endocrine function.

The main questions the study aims to answer are:

Does the program increase the proportion of women who have at least one spontaneous ovulatory menstrual cycle within 12 months? Does it improve hormonal markers of recovery of the hypothalamic-pituitary-ovarian axis, such as LH, FSH, estradiol and T3? Does it improve psychological well-being, stress and eating-related symptoms?

Researchers will compare the program with usual care to see whether the structured program leads to faster or more frequent recovery of menstrual and endocrine function than the care women typically receive today.

Participants will:

Be randomly assigned to the 10-week digital self-help program, delivered via the Swedish healthcare platform 1177 with one module per week (intervention group), or to usual care with a consultation with a gynecologist (comparison group); the comparison group is offered the program after the study Complete questionnaires and a structured diagnostic interview Provide blood samples to measure hormone levels at 3, 6, 9 and 12 months Contact the clinic if menstrual bleeding occurs, so that a blood sample can confirm ovulation Have a gynecological examination with ultrasound after 12 months to assess ovarian activity and endometrial thickness

This study builds on an ongoing feasibility study (NCT07589868) and will help determine whether the program is effective and should be offered more widely to women with FHA.

調査の概要

詳細な説明

The study is a randomized, controlled trial with multicentre recruitment evaluating a 10-week digital psychoeducational health and lifestyle program with 12 months of follow-up in women with functional hypothalamic amenorrhea (FHA).

Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation and self-management skills. The program is compared with usual care to determine whether it leads to superior restoration of ovulatory menstrual cycles and endocrine function.

Study Aim To evaluate whether a 10-week digital psychoeducational program, compared with usual care, increases the proportion of women with FHA who recover spontaneous ovulatory menstrual cycles within 12 months.

Study Setting and Participants Seventy women aged 18-40 years with FHA (amenorrhea for ≥3 months and with a hypothalamic hormone profile: FSH <10 IU/L, LH <10 IU/L and estradiol <200 pmol/L after exclusion of other causes of amenorrhea) are recruited through several gynecological clinics, with central coordination at Karolinska University Hospital. Individuals who meet exclusion criteria receive appropriate clinical information, standard care or referral to relevant healthcare services.

Intervention and Comparator The intervention is a 10-week self-help program delivered via the Swedish healthcare platform 1177 (Stöd och behandling) with one module per week and no therapist support. The comparison group receives usual care, including a consultation with a gynecologist with standard information about FHA, and is offered the program after the 12-month follow-up.

Sample Size In the only previous randomized trial (Berga et al. 2003), ovarian activity recovered in 87.5% of women receiving individual cognitive behavioural therapy compared with 25% with observation. Because small trials tend to overestimate effects, and because the present intervention is a digital self-help program with a stricter primary outcome, a difference of 60% versus 25% is assumed. With 80% power and two-sided α = 0.05, 30 evaluable participants per arm are required. Allowing for 15% attrition, 35 participants per arm (70 in total) will be randomized.

Study Design and Assessments Two-arm, parallel-group superiority trial with 1:1 allocation. Randomization is performed centrally by Karolinska Trial Alliance, stratified by FHA severity at baseline (severe: estradiol <80 pmol/L and LH <2.4 IU/L), with randomly varying block sizes. At the screening visit, all individuals complete the DIAMOND screening questions and the complete eating disorder module, with further modules after a positive screening question. Validated questionnaires (including EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6) and blood sampling (LH, FSH, estradiol, T3 and other hormones) are performed at baseline and at 3, 6, 9 and 12 months, with gynecological follow-up by video or in person. A gynecological examination with transvaginal ultrasound is performed at 12 months.

Data and Sample Collection Questionnaire data are collected electronically via REDCap. Findings from the feasibility study (NCT07589868) and the qualitative interview study inform the final protocol. Participants contact the clinic if menstrual bleeding occurs, and serum progesterone is measured on cycle day 21, counting the first day of bleeding as day 1, to assess ovulation.

Outcome Measures The primary outcome is the proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above [threshold] nmol/L) within 12 months. Secondary outcomes include time to first ovulatory cycle, number of spontaneous cycles, sustained recovery (≥3 consecutive cycles), change in LH, FSH, estradiol and T3, ultrasound signs of ovarian activity, psychological symptoms and well-being, and adverse events.

Statistical Analysis The primary analysis follows the intention-to-treat principle and compares the proportion with at least one spontaneous ovulatory cycle between groups, with the risk difference and 95% confidence interval and logistic regression adjusted for the stratification factor. Missing primary outcome data are handled with multiple imputation, with complete-case and worst-case sensitivity analyses. Secondary menstrual outcomes are analyzed with time-to-event methods and longitudinal outcomes with methods for repeated measurements. A detailed statistical analysis plan will be finalized before database lock.

Ethical Considerations Informed consent is obtained from all participants. The project is approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01, with amendments 2025-07620-02 and 2026-06250-02). The overall risk to participants is considered low, and adverse events are monitored throughout the study period.

研究の種類

介入

入学 (推定)

70

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Stockholm、スウェーデン
        • Kvinnohälsan Karolinska Universitetssjukhuset

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~40年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion criteria:

  • Women aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist
  • amenorrhea for at least 3 months
  • a history compatible with functional hypothalamic amenorrhea
  • exclusion of other causes of amenorrhea
  • able to read and understand Swedish
  • access to an internet-enabled device and BankID
  • written informed consent.

Exclusion criteria:

  • Current anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion)
  • severe psychiatric comorbidity requiring other or more intensive care, including psychosis
  • insufficient Swedish proficiency
  • other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Psychoeducational Intervention

Behavioral: HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months.

HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months.

アクティブコンパレータ:Treatment as Usual (TAU)

Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months; access to the program offered after 12 months.

Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of participants with return of spontaneous menstrual bleeding within 12 months from baseline.
時間枠:Restoration of menstruation after 12 months of follow-up from baseline.

Proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above 13 nmol/L. [Time frame: 12 months].

Restoration of menstruation after 12 months of follow-up from baseline.

二次結果の測定

結果測定
メジャーの説明
時間枠
Time to spontaneous ovulatory cycles within 12 months from baseline.
時間枠:Baseline to 12 months

Time to first spontaneous ovulatory cycle; number of spontaneous cycles; sustained recovery (≥3 consecutive spontaneous cycles)

Baseline to 12 months
Change in BMI within 12 months from baseline.
時間枠:6 and 12 months from baseline

Weight and height will be combined to report BMI in kg/m^2

6 and 12 months from baseline
Change in serum luteinizing hormone (LH)
時間枠:Baseline to 12 months (also assessed at 3, 6 and 9 months)

Change from baseline in serum luteinizing hormone (LH).

Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in serum follicle-stimulating hormone (FSH)
時間枠:Baseline to 12 months (also assessed at 3, 6 and 9 months)

Change from baseline in serum FSH (IU/L).

Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in serum estradiol (E2)
時間枠:Baseline to 12 months (also assessed at 3, 6 and 9 months)

Change from baseline in serum estradiol (pmol/L), sensitive LC-MS/MS method.

Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in serum triiodothyronine (T3)
時間枠:Baseline to 12 months (also assessed at 3, 6 and 9 months)

Change from baseline in serum T3 ([nmol/L or pmol/L, if free T3 - check with the laboratory]).

Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in eating disorder symptoms (EDE-Q)
時間枠:Baseline to 12 months

Change from baseline in Eating Disorder Examination Questionnaire 6.0 global score (range 0-6; higher scores indicate more symptoms).

Baseline to 12 months
Change in perceived stress (PSS-14)
時間枠:Baseline to 12 months

Change from baseline in Perceived Stress Scale total score (range 0-56; higher scores indicate more stress).

Baseline to 12 months
Change in anxiety symptoms (GAD-7)
時間枠:Baseline to 12 months

Change from baseline in GAD-7 total score (range 0-21; higher scores indicate more anxiety).

Baseline to 12 months
Change in depressive symptoms (PHQ-9)
時間枠:Baseline to 12 months

Change from baseline in PHQ-9 total score (range 0-27; higher scores indicate more depressive symptoms).

Baseline to 12 months
Change in well-being (WHO-5)
時間枠:Baseline to 12 months

Change from baseline in WHO-5 percentage score (range 0-100; higher scores indicate better well-being).

Baseline to 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年9月1日

一次修了 (推定)

2028年9月1日

研究の完了 (推定)

2030年12月31日

試験登録日

最初に提出

2026年1月19日

QC基準を満たした最初の提出物

2026年1月27日

最初の投稿 (実際)

2026年2月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2023-05586-01
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

What data will be shared:

De-identified individual participant data collected during the trial, including:

Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments

Other documents to be shared:

Data dictionary describing all variables and coding used Study protocol and statistical analysis plan

IPD 共有時間枠

When data will become available and for how long:

Data will be available 6 months after publication of the primary trial results and will remain accessible for 5 years.

IPD 共有アクセス基準

By what access criteria:

Data will be available to qualified researchers for scientific purposes following submission of a research proposal and approval by the trial steering committee. Requests should be sent to the corresponding author or data custodian (contact information provided in the study publication).Data will be shared via a secure data repository

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する